ADMA BIOLOGICS, INC. Quarterly Cost of Revenue in USD from Q2 2016 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate cost of goods produced and sold and services rendered during the reporting period.
Summary
Adma Biologics, Inc. quarterly/annual Cost of Revenue history and growth rate from Q2 2016 to Q3 2024.
  • Adma Biologics, Inc. Cost of Revenue for the quarter ending September 30, 2024 was $60.2M, a 41.2% increase year-over-year.
  • Adma Biologics, Inc. Cost of Revenue for the twelve months ending September 30, 2024 was $196M, a 20.5% increase year-over-year.
  • Adma Biologics, Inc. annual Cost of Revenue for 2023 was $169M, a 42.5% increase from 2022.
  • Adma Biologics, Inc. annual Cost of Revenue for 2022 was $119M, a 48.9% increase from 2021.
  • Adma Biologics, Inc. annual Cost of Revenue for 2021 was $79.8M, a 30.1% increase from 2020.
Cost of Revenue, Trailing 12 Months (USD)
Cost of Revenue, Quarterly (USD)
Cost of Revenue, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $196M $60.2M +$17.6M +41.2% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $178M $49.7M +$6.31M +14.5% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $172M $42.8M +$2.37M +5.86% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $169M $42.8M +$7.01M +19.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 $162M $42.6M +$11.2M +35.6% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $151M $43.4M +$17.3M +66.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $134M $40.4M +$15M +58.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $119M $35.8M +$12.9M +56.5% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 $106M $31.4M +$11.1M +54.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $94.7M $26.1M +$7.3M +38.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $87.4M $25.4M +$7.67M +43.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $79.8M $22.9M +$3.76M +19.7% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 $76M $20.3M +$8.44M +71.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $67.6M $18.8M +$5.34M +39.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-10
Q1 2021 $62.2M $17.8M +$941K +5.59% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-11
Q4 2020 $61.3M $19.1M +$7.42M +63.5% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-24
Q3 2020 $53.9M $11.9M +$3.94M +49.8% Jul 1, 2020 Sep 30, 2020 10-Q 2020-11-05
Q2 2020 $49.9M $13.5M +$3M +28.6% Apr 1, 2020 Jun 30, 2020 10-Q 2020-08-05
Q1 2020 $46.9M $16.8M +$7.42M +78.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-12
Q4 2019 $39.5M $11.7M +$549K +4.93% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-25
Q3 2019 $39M $7.92M -$1.25M -13.6% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $40.2M $10.5M +$846K +8.77% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 $39.4M $9.41M -$2.84M -23.2% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-06
Q4 2018 $42.2M $11.1M -$2.21M -16.6% Oct 1, 2018 Dec 31, 2018 10-K 2019-03-13
Q3 2018 $44.4M $9.16M -$2.13M -18.8% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-06
Q2 2018 $46.5M $9.65M +$5.31M +123% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 $41.2M $12.2M +$12.1M +6613% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
Q4 2017 $29.2M $13.4M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-13
Q3 2017 $11.3M +$11M +3355% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-09
Q2 2017 $4.33M +$3.95M +1033% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-10
Q1 2017 $182K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-14
Q3 2016 $327K Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-03
Q2 2016 $383K Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.